ECSP20032306A - Análogos de incretina y sus usos - Google Patents

Análogos de incretina y sus usos

Info

Publication number
ECSP20032306A
ECSP20032306A ECSENADI202032306A ECDI202032306A ECSP20032306A EC SP20032306 A ECSP20032306 A EC SP20032306A EC SENADI202032306 A ECSENADI202032306 A EC SENADI202032306A EC DI202032306 A ECDI202032306 A EC DI202032306A EC SP20032306 A ECSP20032306 A EC SP20032306A
Authority
EC
Ecuador
Prior art keywords
incretine
analogues
activity
receptors
incretin analogs
Prior art date
Application number
ECSENADI202032306A
Other languages
English (en)
Inventor
Hongchang Qu
Tamer Coskun
Lili Guo
Jorge Alsina-Fernandez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP20032306A publication Critical patent/ECSP20032306A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Details Of Garments (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan análogos de incretina que tienen actividad en cada uno de los receptores GIP, GLP-1 y glucagón. Los análogos de incretina tienen características estructurales que dan como resultado una actividad equilibrada y una duración de acción extendida en cada uno de estos receptores. También se proporcionan métodos para tratar enfermedades tales como diabetes mellitus, dislipidemia, hepatopatía grasa, síndrome metabólico, esteatohepatitis no alcohólica y obesidad.
ECSENADI202032306A 2017-12-21 2020-06-19 Análogos de incretina y sus usos ECSP20032306A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762608644P 2017-12-21 2017-12-21

Publications (1)

Publication Number Publication Date
ECSP20032306A true ECSP20032306A (es) 2020-07-31

Family

ID=65003515

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202032306A ECSP20032306A (es) 2017-12-21 2020-06-19 Análogos de incretina y sus usos

Country Status (26)

Country Link
US (2) US11834486B2 (es)
EP (1) EP3727425A1 (es)
JP (2) JP6987993B2 (es)
KR (1) KR102440323B1 (es)
CN (1) CN111511387A (es)
AR (1) AR113487A1 (es)
AU (1) AU2018388895B2 (es)
BR (1) BR112020010410A2 (es)
CA (1) CA3084004C (es)
CL (1) CL2020001636A1 (es)
CO (1) CO2020006253A2 (es)
CR (1) CR20200256A (es)
DO (1) DOP2020000124A (es)
EA (1) EA202091284A1 (es)
EC (1) ECSP20032306A (es)
IL (2) IL325352A (es)
JO (1) JOP20200136B1 (es)
MA (1) MA51287A (es)
MX (2) MX2020006547A (es)
MY (1) MY199545A (es)
PE (1) PE20200926A1 (es)
PH (1) PH12020551024A1 (es)
SG (1) SG11202004359YA (es)
TW (2) TWI810937B (es)
UA (1) UA127589C2 (es)
WO (1) WO2019125929A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
ES3068975T3 (en) * 2018-07-23 2026-06-03 Lilly Co Eli Gip/glp1 co-agonist compounds
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
WO2021034815A1 (en) * 2019-08-19 2021-02-25 Eli Lilly And Company Methods of making incretin analogs
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
CA3165430A1 (en) * 2020-01-23 2021-07-29 Jorge Alsina-Fernandez Gip/glp1 co-agonist compounds
US20230310630A1 (en) * 2020-07-17 2023-10-05 Hanmi Pharm. Co., Ltd. Therapeutic use of combination comprising triple agonistic long-acting conjugate or triple agonist
JP2023537895A (ja) * 2020-08-14 2023-09-06 ハンミ ファーマシューティカル カンパニー リミテッド 三重活性体持続型結合体を有効成分として含む薬学組成物
WO2022090447A1 (en) 2020-10-30 2022-05-05 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
TW202423476A (zh) 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
CA3219647A1 (en) * 2021-05-26 2022-12-01 The United Bio-Technology (Hengqin) Co., Ltd. Multi agonists and use thereof
WO2022268029A1 (zh) * 2021-06-21 2022-12-29 广东东阳光药业有限公司 Glp-1、gcg和gip受体的三重激动剂
AU2022298662B2 (en) 2021-06-23 2025-06-05 Eli Lilly And Company An incretin analog for use in glycemic control and weight management
KR20240099485A (ko) * 2021-11-19 2024-06-28 메드샤인 디스커버리 아이엔씨. 스테이플화 펩타이드 및 이의 용도
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN117417411B (zh) * 2022-09-28 2025-08-29 广东东阳光药业股份有限公司 Glp-1/gcg/gip三受体激动剂及其用途
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
AU2024215381A1 (en) 2023-01-31 2025-09-18 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
WO2024213022A1 (zh) * 2023-04-11 2024-10-17 上海多米瑞生物技术有限公司 肠促胰素类似物及其制备方法和应用
CN120329412A (zh) * 2023-11-06 2025-07-18 成都奥达生物科技有限公司 一种三激动剂化合物
CN120349393A (zh) * 2023-11-06 2025-07-22 成都奥达生物科技有限公司 一种三激动剂化合物
CN119241684B (zh) * 2024-11-22 2025-02-25 徐州医科大学 一种肠促胰岛素类似物及其用途
GB202418179D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods
GB202418172D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8779103B2 (en) 2009-03-27 2014-07-15 Glaxo Group Limited Drug fusions and conjugates
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
AR103242A1 (es) 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI783244B (zh) 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
EP3217027A1 (de) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Breites einlageelement zum einfassen einer ankerstange
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Also Published As

Publication number Publication date
JP2022043082A (ja) 2022-03-15
US11834486B2 (en) 2023-12-05
US20210221865A1 (en) 2021-07-22
JOP20200136B1 (ar) 2024-04-18
US20240190936A1 (en) 2024-06-13
CO2020006253A2 (es) 2020-05-29
CA3084004A1 (en) 2019-06-27
AU2018388895A1 (en) 2020-06-04
IL275469B1 (en) 2026-01-01
TWI767095B (zh) 2022-06-11
IL325352A (en) 2026-02-01
IL275469A (en) 2020-08-31
SG11202004359YA (en) 2020-06-29
TW202233227A (zh) 2022-09-01
AU2018388895B2 (en) 2020-12-24
JP2021506825A (ja) 2021-02-22
MX2020006547A (es) 2020-12-09
EA202091284A1 (ru) 2020-09-08
BR112020010410A2 (pt) 2020-11-24
CL2020001636A1 (es) 2020-10-16
MA51287A (fr) 2021-03-31
AR113487A1 (es) 2020-05-06
TWI810937B (zh) 2023-08-01
PH12020551024A1 (en) 2021-05-31
CR20200256A (es) 2020-07-12
MX2025003745A (es) 2025-05-02
UA127589C2 (uk) 2023-10-25
PE20200926A1 (es) 2020-09-14
TW201938187A (zh) 2019-10-01
JOP20200136A1 (ar) 2022-10-30
EP3727425A1 (en) 2020-10-28
IL275469B2 (en) 2026-05-01
KR20200088418A (ko) 2020-07-22
CN111511387A (zh) 2020-08-07
MY199545A (en) 2023-11-06
WO2019125929A1 (en) 2019-06-27
KR102440323B1 (ko) 2022-09-05
DOP2020000124A (es) 2020-08-31
CA3084004C (en) 2023-06-20
JP6987993B2 (ja) 2022-01-05
NZ765268A (en) 2024-07-05

Similar Documents

Publication Publication Date Title
ECSP20032650A (es) Análogos de incretina y sus usos
DOP2020000124A (es) Análogos de incretina y sus usos
DOP2022000122A (es) Analogos de incretina y sus usos
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
LT3297653T (lt) Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
MX2023011453A (es) Composiciones para usarse en el tratamiento y prevencion de degeneracion macular.
MX394179B (es) Liraglutida en afecciones cardiovasculares.
AR101592A1 (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cd123
AR103730A1 (es) Método para la administración de droga